DNA Script adds Dr. Heiner Dreismann, former CEO of Roche Molecular Diagnostics, to Board of Directors

Paris, January the 18th, 2017. DNA Script announced today it welcomed Dr. Heiner Dreismann to its board of directors.

Dr. Dreismann, 63, is recognized as a driving force behind the adoption of the polymerase chain reaction (PCR) technique in the 1990s for use in basic research and drug discovery laboratories. PCR technology revolutionized molecular biology allowing researchers to amplify a few copies of a piece of DNA across several orders of magnitude. The technique continues to be important to researchers today, especially in the areas of biotechnology and genetics. While CEO of Roche Molecular Diagnostics, Dr. Dreismann led the development and commercialization of an expansive portfolio of PCR products, sustaining Roche's industry leadership in Molecular Diagnostics.

"Heiner guided the world leader in molecular diagnostics and tools, and we are very proud that he is willing to share his experience and help us accelerate our growth," said Thomas Ybert, chief executive officer of DNA Script. "We look forward to his contribution to our strategic development plan and rapid commercialization of our unique technology."

Dr. Dreismann added, "I believe that DNA Script's technology has the potential to radically transform the genetic engineering industry with a novel enzymatic approach to DNA synthesis, similar to what PCR did in the nineties. It is a privilege to join this exciting and dynamic team, and I look forward to working closely with the management and the board members during the next stages of DNA Script's growth."

About DNA Script
DNA Script is a Paris-based company focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

Its technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. DNA Script develops its technology in partnership with Institut Pasteur and Institut Pierre Gilles de Gennes with the support of key investors such as Sofinnova Partners, Kurma Partners and Idinvest Partners.

www.dnascript.co

Contact
Sylvain Gariel, COO
sg@dnascript.co
+33.6.28.04.53.11
www.dnascript.co